NEOS THERAPEUTICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neos Therapeutics, Inc. To Contact The Firm

NEW YORK, Sept. 20, 2016

The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, on October 19, 2015, the Company disclosed that the U.S. Food and Drug Administration had identified deficiencies in the Company's new drug application for Cotempla XR-ODT that precluded discussion of labeling and marketing requirements at that time. In addition, on August 11, 2016, the Company announced its financial results for its second quarter of 2016, reporting it had missed its earnings expectations by $0.49 per share. As a result of these disclosures, Neos Therapeutics' stock price has significantly declined.

Request more information now by clicking here:  www.faruqilaw.com/NEOS. There is no cost or obligation to you.

Take Action

If you invested in Neos Therapeutics' common stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/NEOS.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Neos Therapeutics' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330